BACKGROUND: Quantitative measurement of HIV-1 RNA levels in plasma ('viral load') plays a central role in clinical management. The choice of assay platform can influence results and treatment decisions. OBJECTIVE: To compare the analytical performance of the new TMA-based Hologic Aptima(®) HIV-1 Quant Dx assay with that of three PCR-based assays: Abbott RealTime HIV-1, Qiagen Artus(®) HI Virus-1 QS-RGQ, and Roche CAP/CTM HIV-1 Test v2. STUDY DESIGN: Assay performance was evaluated using Acrometrix HIV-1 RNA Standard panels; the 3rd WHO HIV-1 RNA International Standard (12-500 copies/ml; 6 dilutions; 9 replicates); and plasma samples from 191 HIV-positive patients. RESULTS: Aptima showed high (>0.99) precision, accuracy and concordance with the Acrometrix Standards across a wide dynamic range (2.0-6.7 log10copies/ml). Variance caused up to 2.1 (Aptima), 1.7 (RealTime), 7.5 (Artus), and 1.9 (CAP/CTM) fold changes in the International Standard quantifications at 50-500 copies/ml. HIV-1 RNA detection rates in plasma samples were 141/191 (74%), 119/191 (62%), 108/191 (57%), and 145/191 (76%) for Aptima, RealTime, Artus and CAP/CTM, respectively. For categorising samples either side of 50 copies/ml, Aptima had excellent agreement with RealTime (kappa 0.92; 95% CI 0.87-0.98); lowest agreement was with Artus (kappa 0.79; 95%CI 0.70-0.88). Aptima quantifications were mean 0.12 and 0.06 log10copies/ml higher compared with RealTime and CAP/CTM, respectively, and 0.05 log10copies/ml lower compared with Artus. Limits of agreement were narrowest when comparing Aptima to RealTime. CONCLUSIONS: The new Aptima HIV assay is sensitive, precise, and accurate. HIV assays exhibit discordance at low HIV-1 RNA copy numbers.
BACKGROUND: Quantitative measurement of HIV-1 RNA levels in plasma ('viral load') plays a central role in clinical management. The choice of assay platform can influence results and treatment decisions. OBJECTIVE: To compare the analytical performance of the new TMA-based Hologic Aptima(®) HIV-1 Quant Dx assay with that of three PCR-based assays: Abbott RealTime HIV-1, Qiagen Artus(®) HI Virus-1 QS-RGQ, and Roche CAP/CTMHIV-1 Test v2. STUDY DESIGN: Assay performance was evaluated using Acrometrix HIV-1 RNA Standard panels; the 3rd WHO HIV-1 RNA International Standard (12-500 copies/ml; 6 dilutions; 9 replicates); and plasma samples from 191 HIV-positive patients. RESULTS: Aptima showed high (>0.99) precision, accuracy and concordance with the Acrometrix Standards across a wide dynamic range (2.0-6.7 log10copies/ml). Variance caused up to 2.1 (Aptima), 1.7 (RealTime), 7.5 (Artus), and 1.9 (CAP/CTM) fold changes in the International Standard quantifications at 50-500 copies/ml. HIV-1 RNA detection rates in plasma samples were 141/191 (74%), 119/191 (62%), 108/191 (57%), and 145/191 (76%) for Aptima, RealTime, Artus and CAP/CTM, respectively. For categorising samples either side of 50 copies/ml, Aptima had excellent agreement with RealTime (kappa 0.92; 95% CI 0.87-0.98); lowest agreement was with Artus (kappa 0.79; 95%CI 0.70-0.88). Aptima quantifications were mean 0.12 and 0.06 log10copies/ml higher compared with RealTime and CAP/CTM, respectively, and 0.05 log10copies/ml lower compared with Artus. Limits of agreement were narrowest when comparing Aptima to RealTime. CONCLUSIONS: The new Aptima HIV assay is sensitive, precise, and accurate. HIV assays exhibit discordance at low HIV-1 RNA copy numbers.
Authors: Wen Hui Shaw; Qianqian Lin; Zikry Zhiwei Bin Roslee Muhammad; Jia Jun Lee; Wei Xin Khong; Oon Tek Ng; Eng Lee Tan; Peng Li Journal: J Clin Diagn Res Date: 2016-07-01
Authors: Malaya K Sahoo; Vici Varghese; Elizabeth White; Meg Winslow; David A Katzenstein; Robert W Shafer; Benjamin A Pinsky Journal: J Clin Microbiol Date: 2016-08-17 Impact factor: 5.948
Authors: Mark M Manak; Holly R Hack; Sangeetha V Nair; Andrew Worlock; Jennifer A Malia; Sheila A Peel; Linda L Jagodzinski Journal: J Clin Microbiol Date: 2016-08-10 Impact factor: 5.948
Authors: Philip J Norris; Jinbing Zhang; Andrew Worlock; Sangeetha V Nair; Kathryn Anastos; Howard L Minkoff; Maria C Villacres; Mary Young; Ruth M Greenblatt; Seema Desai; Alan L Landay; Stephen J Gange; C Thomas Nugent; Elizabeth T Golub; Sheila M Keating Journal: Open Forum Infect Dis Date: 2016-02-08 Impact factor: 3.835
Authors: Frank Wiesmann; Robert Ehret; Gudrun Naeth; Martin Däumer; Jörg Fuhrmann; Rolf Kaiser; Christian Noah; Martin Obermeier; Gunnar Schalasta; Carsten Tiemann; Eva Wolf; Heribert Knechten; Patrick Braun Journal: J Clin Microbiol Date: 2018-09-25 Impact factor: 5.948